Skip to content

Author

H. Heerspink

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

BACKGROUND AND AIMS Hypertension is a common attributable cause of chronic kidney disease (CKD). Mineralocorticoid receptor overactivation can lead to hypertension and contributes to CKD progression. In FIND-CKD, finerenone reduced kidney function decline in participants with CKD without diabetes. This prespecified FIN...

H. Heerspink, Jelle M. Beernink, R. Agarwal et al. · 0 citations
Open access Sep 2026

Initial Changes in eGFR during Treatment with Balcinrenone and Dapagliflozin: An Exploratory Analysis of the MIRO-CKD Trial.

INTRODUCTION The novel non-steroidal mineralocorticoid receptor antagonist balcinrenone in combination with dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) over 12 weeks in the MIRO-CKD phase 2 trial in chronic kidney disease (CKD) and induced a modest acute eGFR reduction upon treatment initiation. Th...

H. Heerspink, Erika de Sousa Amorim, Jelle M. Beernink et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.